# NCT06905197 (NCT06905197)

> A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06905197
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Dizal Pharmaceuticals
- Conditions: Non Small Cell Lung Cancer
- Interventions: DZD6008; Sunvozertinib
- Enrollment: 140
- Primary outcome: Part A: To assess safety and tolerability
- Primary outcome: Part A: To assess safety and tolerability
- Primary outcome: Part B: To assess anti-tumor activity

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06905197